LONA Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 12.82%, SMA50 -3.34%, SMA200 30.8%). The stock’s 14-day RSI is 54.86 (neutral), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.78% below its high and over 155.98% above its low. Average 10-day trading volume of 62.85 thousand shares is in line with the 3-month average of 59.98 thousand, indicating normal recent market interest.

LeonaBio, Inc. generated EPS of -$9.66 over the past year. Five-year average earnings growth is -72.27%. Wall Street analysts project EPS growth of 56.46% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $10.00. The high target offers 106.83% upside. The low target suggests 3.41% downside. The mean target is $15.00. This offers 55.12% upside. LeonaBio, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 07, 2026, missed forecasts by -24.03%. The prior quarter beat by 1300.34%. Over the last six quarters, Apple has recorded several small beats. These include 69.57% in February 27, 2025.

LeonaBio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $16.01. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that LeonaBio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.62%, with price expected at $9.73 by June 09, 2026, within a range of $8.65 to $10.81 3-Month Outlook: Projected rise of 24.51%, reaching $12.04 by August 24, 2026, with a range of $11.91 to $12.17. 1-Year Outlook: Projected gain of 151.4%, with price at $24.31 by May 26, 2027, within a range of $24.20 to $24.43.

LeonaBio, Inc. (NASDAQ:LONA) shares are down -17.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows LeonaBio, Inc. trading at a premium to the broader market with a P/E of -1.46. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $15.00, suggesting 55.12% upside. Our AI forecast model points to short-term strength (0.62% over two weeks), a medium-term rise (24.51% over three months), and a longer-term gain (151.4% over one year), with expected trading ranges indicating moderate volatility.

LeonaBio, Inc. (NASDAQ:LONA) closed at $9.77 USD, gaining $0.10 (1.03%) from the previous close of $9.67. The stock is currently mid-range between its 52-week high and low $4.25 and $11.91. With a market capitalization of about $38.53 million, LeonaBio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.98). Headquartered in Bothell, WA, LeonaBio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mark J. Litton, the company employs approximately 26 people and listed since September 18, 2020. LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.

LeonaBio, Inc. trades at a P/E ratio of -1.46, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.84 trading at moderately above to book value. The P/FCF stands at -0.76, also below market averages.